Literature DB >> 1872336

Polycystic ovary syndrome and the androgen-insulin connection.

S Nader1.   

Abstract

The association of hyperandrogenism, insulin resistance, and polycystic ovarian disease is well established. The accompanying hyperinsulinemia results in acanthosis nigricans, an epiphenomenon of this syndrome. The knowledge that states of insulin resistance of diverse causes are associated with ovarian hyperandrogenism makes the argument for insulin-driven ovarian androgen secretion compelling. However, equally compelling evidence suggests that hyperandrogenism may contribute to insulin resistance and hyperinsulinemia. The irreconcilable differences between these two hypotheses have resulted in an array of contradictory studies. In this article a unified concept of polycystic ovary syndrome and its androgen-insulin connection is proposed. The hypothesis incorporates the role of hyperinsulinemia in the androgen excess observed (and vice versa); the key to this connection is the androgen-dependent change in regional body fat distribution and its metabolic consequence. The pathophysiologic features of polycystic ovary syndrome, which has important clinical sequelae, deserve further consideration.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1872336     DOI: 10.1016/0002-9378(91)90089-a

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  2 in total

Review 1.  Unsolved Mysteries of the Human Mammary Gland: Defining and Redefining the Critical Questions from the Lactation Consultant's Perspective.

Authors:  Lisa Ann Marasco
Journal:  J Mammary Gland Biol Neoplasia       Date:  2015-06-18       Impact factor: 2.673

2.  Serum androgens in hyperinsulinemic Pima Indian and obese Caucasian women and their response to short-term insulin infusion.

Authors:  S Nader; M A Charles; M F Saad; A S Berkowitz; C Bogardus
Journal:  J Endocrinol Invest       Date:  1993-06       Impact factor: 4.256

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.